Trimetrexate

Base Information

• Chemical Name: Trimetrexate
• CAS No.: 52128-35-5
• Molecular Formula: C19H23N5O3
• Molecular Weight: 369.423
• Hs Code.: 2933990090
• European Community (EC) Number: 615-840-9
• NSC Number: 249008
• UNII: UPN4ITI8T4
• DSSTox Substance ID: DTXSID3023714
• Nikkaji Number: J22.060D
• Wikipedia: Trimetrexate
• Wikidata: Q7842225
• NCI Thesaurus Code: C1314
• Pharos Ligand ID: LUKLVMNYM2FR
• Metabolomics Workbench ID: 43377
• ChEMBL ID: CHEMBL119
• Mol file: 52128-35-5.mol

Synonyms:CI 898;CI-898;CI898;Hydrate, Trimetrexate;JB 11;JB-11;JB11;Monohydrate, Monoacetate Trimetrexate;NSC 249008;NSC 328564;NSC-249008;NSC-328564;NSC249008;NSC328564;Trimetrexate;Trimetrexate Hydrate;Trimetrexate Monohydrate, Monoacetate

Chemical Property of Trimetrexate

Chemical Property:

• Vapor Pressure: 1.34E-19mmHg at 25°C
• Melting Point: 215-217 °C
• Boiling Point: 647 °C at 760 mmHg
• PKA: 8.09±0.30(Predicted)
• Flash Point: 345.1 °C
• PSA: 117.54000
• Density: 1.305g/cm³
• LogP: 3.97590
• Storage Temp.: 2-8°C(protect from light)
• XLogP3: 2.5
• Hydrogen Bond Donor Count: 3
• Hydrogen Bond Acceptor Count: 8
• Rotatable Bond Count: 6
• Exact Mass: 369.18008961
• Heavy Atom Count: 27
• Complexity: 457

Purity/Quality:

98%min ^*data from raw suppliers

Trimetrexate ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Drug Classes: Antineoplastic Agents
• Canonical SMILES: CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC
• Description: Trimetrexate (TMQ) has been approved for the treatment of Pneumocystis carinii in patients with AIDS and also exhibits antiprotozoal activity against Trypanosoma cruzi . The drug is available as a single-ingredient medication, but it can be administered along with folinic acid in much the same way that methotrexate is administered with calcium leucovorin in cancer chemotherapy. Trimetrexate is a derivative of methotrexate.
• Uses: Antineoplastic. Trimetrexate is an FDA-approved drug which selectively inhibits Streptococcus mutans through targeting dihydrofolate reductase (DHFR).
• Clinical Use: Trimetrexate, when combined with the cytoprotective agent leucovorin, is more effective and better tolerated than pentamidine in the treatment of PCP. Because the first- and second-line agents are successful in only 50 to 75% of these cases, and because adverse reactions severely limit the use of some of the older agents, TMQ may offer some advantages in treatment. Trimetrexate is administered by IV infusion over 60 to 90 minutes and should be combined with the cytoprotective drug leucovorin. The leucovorin protects against bone marrow suppression and against renal and hepatic dysfunction. Leucovorin administration should continue for 72 hours after the last dose of TMQ. Additionally, TMQ has been reported to be effective in the treatment of Chagas' disease.

Technology Process of Trimetrexate

There total 2 articles about Trimetrexate which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield:

quinazoline (253-82-7) + 3,4,5-Trimethoxyaniline (24313-88-0) + 2,4-diamino-5-methyl-6-quinazolinecarbonitrile (18917-72-1) → trimetrexate (52128-35-5)

Guidance literature:

With hydrogen; acetic acid; aluminum nickel; In water; ethyl acetate; N,N-dimethyl-formamide;

Reference yield:

→ trimetrexate (52128-35-5)

Guidance literature:

upstream raw materials:

quinazoline

3,4,5-Trimethoxyaniline

2,4-diamino-5-methyl-6-quinazolinecarbonitrile

Refernces

• 1、 -. "Insecticidal substituted-2,4-diaminoquinazolines". . . Retrieved 2008/06/13.